NK Cells Stimulate Recruitment of cDC1 into the Tumor Microenvironment Promoting Cancer Immune Control

[1]  N. Waddell,et al.  Interleukin-12 from CD103+ Batf3-Dependent Dendritic Cells Required for NK-Cell Suppression of Metastasis , 2017, Cancer Immunology Research.

[2]  T. Gajewski,et al.  Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy. , 2017, Cancer cell.

[3]  Benjamin D. Greenbaum,et al.  Innate Immune Landscape in Early Lung Adenocarcinoma by Paired Single-Cell Analyses , 2017, Cell.

[4]  N. Hacohen,et al.  Single-cell RNA-seq reveals new types of human blood dendritic cells, monocytes, and progenitors , 2017, Science.

[5]  F. Klauschen,et al.  CD8+ T Cells Orchestrate pDC‐XCR1+ Dendritic Cell Spatial and Functional Cooperativity to Optimize Priming , 2017, Immunity.

[6]  N. McGovern,et al.  Human lymphoid organ dendritic cell identity is predominantly dictated by ontogeny, not tissue microenvironment , 2016, Science Immunology.

[7]  Camille Guillerey,et al.  Targeting natural killer cells in cancer immunotherapy , 2016, Nature Immunology.

[8]  T. Kaisho,et al.  Critical Role for CD103(+)/CD141(+) Dendritic Cells Bearing CCR7 for Tumor Antigen Trafficking and Priming of T Cell Immunity in Melanoma. , 2016, Cancer cell.

[9]  M. Pittet,et al.  The role of myeloid cells in cancer therapies , 2016, Nature Reviews Cancer.

[10]  Alex Boussioutas,et al.  Cross-validation of survival associated biomarkers in gastric cancer using transcriptomic data of 1,065 patients , 2016, Oncotarget.

[11]  Laura F. Dagley,et al.  CIS is a potent checkpoint in NK cell–mediated tumor immunity , 2016, Nature Immunology.

[12]  F. Ginhoux,et al.  Expansion and Activation of CD103(+) Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition. , 2016, Immunity.

[13]  F. Ginhoux,et al.  Crucial roles of XCR1-expressing dendritic cells and the XCR1-XCL1 chemokine axis in intestinal immune homeostasis , 2016, Scientific Reports.

[14]  T. Taniguchi,et al.  PGE2 induced in and released by dying cells functions as an inhibitory DAMP , 2016, Proceedings of the National Academy of Sciences.

[15]  Lisa M. Coussens,et al.  The Basis of Oncoimmunology , 2016, Cell.

[16]  K. Crozat,et al.  XCR1+ dendritic cells promote memory CD8+ T cell recall upon secondary infections with Listeria monocytogenes or certain viruses , 2016, The Journal of experimental medicine.

[17]  María Martínez-López,et al.  Cancer Immunotherapy with Immunomodulatory Anti-CD137 and Anti-PD-1 Monoclonal Antibodies Requires BATF3-Dependent Dendritic Cells. , 2016, Cancer discovery.

[18]  Erik Sahai,et al.  Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity , 2015, Cell.

[19]  Nicolas Serafini,et al.  Transcriptional regulation of innate lymphoid cell fate , 2015, Nature Reviews Immunology.

[20]  Michael Poidinger,et al.  Identification of cDC1- and cDC2-committed DC progenitors reveals early lineage priming at the common DC progenitor stage in the bone marrow , 2015, Nature Immunology.

[21]  F. Rosenbauer,et al.  Batf3 maintains Irf8 autoactivation for commitment of a CD8α+ cDC clonogenic progenitor , 2015, Nature Immunology.

[22]  T. Gajewski,et al.  Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity , 2015, Nature.

[23]  S. Kaech,et al.  Prostaglandin E2 and programmed cell death 1 signaling coordinately impair CTL function and survival during chronic viral infection , 2015, Nature Medicine.

[24]  B. Volkman,et al.  Structural and agonist properties of XCL2, the other member of the C-chemokine subfamily. , 2015, Cytokine.

[25]  M. Merad,et al.  Selective and efficient generation of functional Batf3-dependent CD103+ dendritic cells from mouse bone marrow. , 2014, Blood.

[26]  Vivien W. Chan,et al.  Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells. , 2014, Cancer cell.

[27]  R. Pestell,et al.  The potential to target CCL5/CCR5 in breast cancer , 2014, Expert opinion on therapeutic targets.

[28]  Florent Ginhoux,et al.  Dendritic cells, monocytes and macrophages: a unified nomenclature based on ontogeny , 2014, Nature Reviews Immunology.

[29]  Jeffrey W Pollard,et al.  Tumor-associated macrophages: from mechanisms to therapy. , 2014, Immunity.

[30]  Sebastian Amigorena,et al.  Dissecting the Tumor Myeloid Compartment Reveals Rare Activating Antigen-Presenting Cells Critical for T Cell Immunity. , 2014, Cancer cell.

[31]  H. Schreiber,et al.  Innate and adaptive immune cells in the tumor microenvironment , 2013, Nature Immunology.

[32]  Miriam Merad,et al.  The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting. , 2013, Annual review of immunology.

[33]  K. Murphy,et al.  DNGR-1 is a specific and universal marker of mouse and human Batf3-dependent dendritic cells in lymphoid and nonlymphoid tissues. , 2012, Blood.

[34]  P. Queirolo,et al.  Melanoma cells inhibit natural killer cell function by modulating the expression of activating receptors and cytolytic activity. , 2012, Cancer research.

[35]  P. Kalinski.  Regulation of Immune Responses by Prostaglandin E2 , 2012, The Journal of Immunology.

[36]  R. Schreiber,et al.  Natural innate and adaptive immunity to cancer. , 2011, Annual review of immunology.

[37]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[38]  N. Friedman,et al.  Densely Interconnected Transcriptional Circuits Control Cell States in Human Hematopoiesis , 2011, Cell.

[39]  P. Kloetzel,et al.  Superior antigen cross-presentation and XCR1 expression define human CD11c+CD141+ cells as homologues of mouse CD8+ dendritic cells , 2010, The Journal of experimental medicine.

[40]  E. Gorelik,et al.  Receptor desensitization and blockade of the suppressive effects of prostaglandin E2 and adenosine on the cytotoxic activity of human melanoma-infiltrating T lymphocytes , 2010, Cancer Immunology, Immunotherapy.

[41]  F. Ginhoux,et al.  The origin and development of nonlymphoid tissue CD103+ DCs , 2009, The Journal of experimental medicine.

[42]  Andreas Hutloff,et al.  Selective expression of the chemokine receptor XCR1 on cross-presenting dendritic cells determines cooperation with CD8+ T cells. , 2009, Immunity.

[43]  A. Hayday.  Gammadelta T cells and the lymphoid stress-surveillance response. , 2009, Immunity.

[44]  D. Raulet,et al.  Oncogenic stress sensed by the immune system: role of natural killer cell receptors , 2009, Nature Reviews Immunology.

[45]  A. Rudensky,et al.  In Vivo Analysis of Dendritic Cell Development and Homeostasis , 2009, Science.

[46]  E. Unanue,et al.  Batf3 Deficiency Reveals a Critical Role for CD8α+ Dendritic Cells in Cytotoxic T Cell Immunity , 2008, Science.

[47]  A. Cerwenka,et al.  Natural killer cell accumulation in tumors is dependent on IFN-gamma and CXCR3 ligands. , 2008, Cancer research.

[48]  D. Koller,et al.  The Immunological Genome Project: networks of gene expression in immune cells , 2008, Nature Immunology.

[49]  D. Pennington,et al.  Tumor therapy in mice via antigen targeting to a novel, DC-restricted C-type lectin. , 2008, The Journal of clinical investigation.

[50]  Eric Vivier,et al.  Novel insights into the relationships between dendritic cell subsets in human and mouse revealed by genome-wide expression profiling , 2008, Genome Biology.

[51]  Eric J. Brown,et al.  The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor , 2005, Nature.

[52]  K. Subbaramaiah,et al.  Targeting cyclooxygenase-2 in human neoplasia: rationale and promise. , 2003, Cancer cell.

[53]  S. McColl.  Chemokines and dendritic cells: A crucial alliance , 2002, Immunology and cell biology.

[54]  A. Diefenbach,et al.  Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity , 2001, Nature.